No Data
No Data
No Data
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): plans to use temporarily idle raised funds with a limit of no more than 0.3 billion yuan (including principal) for cash management.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced on July 17 that the Fourth Board of Directors and the Ninth Supervisory Board of the Fourth Session will be held on July 17, 2024. The "Proposal on Using Temporarily Idle Raised Funds for Cash Management" was reviewed and approved, agreeing that the company can use temporarily idle raised funds not exceeding RMB 300 million (including the principal) for cash management, of which the amount of temporarily idle raised funds for the first public issue of stocks does not exceed RMB 150 million (including the principal), and the stocks will be issued to specific parties through a simplified procedure.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (Stock Code: 688566.SH) announced Q1 2024 equity distribution of CNY 0.26 per share on July 9, with the ownership registration.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (SH: 688566) has issued an announcement on the implementation of equity distribution for the first quarter of 2024. The profit distribution this time will be based on...
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) plans to distribute 2.6 yuan per 10 shares in the first quarter.
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced that the company plans to distribute equity shares as dividends in the first quarter of 2024...
Gibbel (688566.SH): The application for a fixed increase was reviewed and approved by the Shanghai Stock Exchange
GLONGHUI, May 9, 丨 Jiber (688566.SH) announced that the company received an audit opinion from the Shanghai Stock Exchange on the company's application to issue A shares to specific targets using a simple procedure in 2023: According to the “Shanghai Stock Exchange Listed Company Securities Issuance and Listing Review Rules”, Jiangsu Gibel Pharmaceutical Co., Ltd. met the issuance conditions, listing conditions and information disclosure requirements by issuing shares to specific targets through simple procedures.
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Gibbel (688566.SH) released 2023 annual results, with net profit of 219 million yuan, an increase of 41.65% over the previous year
Gibbel (688566.SH) released its 2023 annual report. The company achieved operating income of 8.6 during the reporting period...
No Data